AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines. Its primary revenue sources come from a diverse portfolio of products, with significant contributions from oncology (approximately 40%), cardiovascular and renal (around 30%), and respiratory (about 20%). The company serves a global customer base, including primary care and specialty care physicians, through various distribution channels. Factors supporting its endurance include a strong pipeline of new drugs and established relationships with healthcare providers, while challenges may arise from patent expirations and competition from generic drugs.
—
AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines. Its primary revenue sources come from a diverse portfolio of products, with significant contributions from oncology (approximately 40%), cardiovascular and renal (around 30%), and respiratory (about 20%). The company serves a global customer base, including primary care and specialty care physicians, through various distribution channels. Factors supporting its endurance include a strong pipeline of new drugs and established relationships with healthcare providers, while challenges may arise from patent expirations and competition from generic drugs.
—
Daily adjusted close
AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines. Its primary revenue sources come from a diverse portfolio of products, with significant contributions from oncology (approximately 40%), cardiovascular and renal (around 30%), and respiratory (about 20%). The company serves a global customer base, including primary care and specialty care physicians, through various distribution channels. Factors supporting its endurance include a strong pipeline of new drugs and established relationships with healthcare providers, while challenges may arise from patent expirations and competition from generic drugs.